Komori
Solasia Pharma K.K. (4597) · InitiativeFirst stated

Securing a Stable Long-Term Funding Base through a Capital and Business Alliance with NIPPON KAYAKU CO.,LTD.

First written in FY2022. . Latest entry: FY2022.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Fundraising for Pharmaceutical Development through New Share Issuances, Out-Licensing and Other MeansA theme 19 companies write about · 0 as a headwind · 25 as a tailwind

1 other company's latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.
Full recordFilings, disclosures and news, newest first
  1. FY2022First statedAnnual report

    「In June 2022, the Company determined that it was important to continue actively pursuing new development products in the cancer field to meet the expectations of cancer patients, patients facing the side effects of anticancer drugs and healthcare professionals. To secure stable long-term funding for this purpose, it entered into a capital and business alliance agreement with NIPPON KAYAKU CO.,LTD., the partner for darinaparsin (SP-02).」

    The Company first explicitly identified the capital and business alliance with NIPPON KAYAKU CO.,LTD., SP-02’s domestic sales partner, as a means of securing stable long-term funding to support new cancer-drug development. On 14 July 2022, it conducted a third-party allotment of 12,000,000 common shares for total proceeds of ¥1,020,000,000, which were to be used for licensing and developing new products.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Solasia Pharma K.K. yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Securing a Stable Long-Term Funding Base through a Capital and Business Alliance with NIPPON KAYAKU CO.,LTD. | Solasia Pharma K.K. (4597) | Komori